Cancer and neoplasms

M25-288 Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Advanced or Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288 (AndroMETa-PDAC-288)

GO TO STUDY

Cancer and neoplasms

BDTX-4933-101 - A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies (BDTX-4933-101)

GO TO STUDY

Cancer and neoplasms

A Phase III, Randomized, Open Label, Multicenter Study Evaluating The Efficacy And Safety Of Cevostamab In Combination With Pomalidomide And Dexamethasone Versus Standard Of Care In Patients With Multiple Myeloma Who Have Received One To Three Prior Lines Of Therapy (CEVOLUTION)

GO TO STUDY

Cancer and neoplasms

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor ABBV-453 given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma

GO TO STUDY

Cancer and neoplasms

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Patients with Newly-Diagnosed AML with an NPM1 mutation (REVEAL-ND NPM1)

GO TO STUDY

Neurological

Effects of N-Acetyl-L-Leucine on CACNA1A Disorders: A Phase III, randomized, placebo-controlled, double-blind, crossover study (IB1001-304)

GO TO STUDY

Blood Cancer and neoplasms

Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions (ELRISE MDS)

GO TO STUDY

Stroke

NeVa One Registry - Prospective, Open-Label, Multi-Center Registry Designed to Assess the Safety, Performance and Efficacy of the NeVa Stent Retriever in the Treatment of Large Vessel Occlusion Strokes (NeVa One)

GO TO STUDY

Neurological

A Phase 2 Open-label Multicenter study to evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in children from 2 years to less than 18 years of age with generalized Myasthenia Gravis (gMG) (THYME)

GO TO STUDY

Exploring the lived experience of patients with Congenital Myasthenic Syndromes (CMS) about assessment tools used clinically and patient view on what might capture meaningful change.

GO TO STUDY